
Lembas is pioneering a new category of science-backed supplements and functional ingredients for healthy and effective weight management. Their core offering, Lembas GLP-1 Edge™, is a natural bioactive peptide that enhances the body's GLP-1 response to promote satiety and manage appetite, integrating seamlessly into various food and beverage products. The company leverages a proprietary AI-powered platform, based on patent-pending university technology, to discover and optimize new bioactive peptides for metabolic health and beyond. Lembas positions itself as a companion for natural, safe, and sustainable weight management, differentiating itself from traditional methods like injections or extreme diets.

Lembas is pioneering a new category of science-backed supplements and functional ingredients for healthy and effective weight management. Their core offering, Lembas GLP-1 Edge™, is a natural bioactive peptide that enhances the body's GLP-1 response to promote satiety and manage appetite, integrating seamlessly into various food and beverage products. The company leverages a proprietary AI-powered platform, based on patent-pending university technology, to discover and optimize new bioactive peptides for metabolic health and beyond. Lembas positions itself as a companion for natural, safe, and sustainable weight management, differentiating itself from traditional methods like injections or extreme diets.
Company: Lembas
Product: GLP-1 Edge™ — a food-based bioactive peptide ingredient to amplify GLP-1 release for appetite and weight management
Business model: B2B ingredient partner for food, beverage and supplement brands
Founded: 2024
Headquarters: Sheffield, United Kingdom
Recent funding: $3.6M Pre-Seed / Seed (Jun 2025)
Weight management, appetite control, metabolic health
2024
Biotechnology
$3.6M
Syndicate includes Siddhi Capital, fresh.fund, Mandi Ventures, Maia Ventures, Longevity Venture Partners, Bluestein Ventures, Skull Diamond And Heart Capital
“Led by FLORA Ventures with participation from several early-stage investors”